QuantuMDx receives CDTA approval for sale of Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay
13. Dezember 2022 02:00 ET
|
QuantuMDx Group Ltd
QuantuMDx receives CDTA approval for sale of Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay NEWCASTLE UPON TYNE, UK 13 December, 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its...
QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform
02. November 2022 08:00 ET
|
QuantuMDx Group Ltd
QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform - Agreement will initially cover the UK and France with potential to expand to other European...
QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform
02. November 2022 03:00 ET
|
QuantuMDx Group Ltd
QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform - Agreement will initially cover the UK and France with potential to expand to other European...
QuantuMDx Enters into Cooperation Agreement with Sansure Biotech
06. September 2022 07:30 ET
|
QuantuMDx Group Ltd
QuantuMDx Enters into Cooperation Agreement with Sansure Biotech The agreement sets a roadmap for the commercialisation of Q-POC™ and its assays in ChinaThe two companies will collaborate to...
QuantuMDx Enters into Cooperation Agreement with Sansure Biotech
06. September 2022 02:00 ET
|
QuantuMDx Group Ltd
QuantuMDx Enters into Cooperation Agreement with Sansure Biotech The agreement sets a roadmap for the commercialisation of Q-POC™ and its assays in ChinaThe two companies will collaborate to...
QuantuMDx launches New PCR Respiratory Panel
26. Mai 2022 02:00 ET
|
QuantuMDx Group Ltd
QuantuMDx launches New PCR Respiratory Panel New multiplex panel can detect SARS-CoV-2, Flu A, Flu B & RSV at the Point of NeedAccurate PCR results delivered in 35 minutes NEWCASTLE UPON TYNE,...
QuantuMDx announces approval of its Rapid Q-POC™ SARS-CoV-2 assay in the UK under CTDA legislation
22. Februar 2022 08:53 ET
|
QuantuMDx Group Ltd
QuantuMDx announces approval of its Rapid Q-POCTM SARS-CoV-2 assay in the UK under CTDA legislation NEWCASTLE UPON TYNE, UK, 22 February 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces...
QuantuMDx confirm its diagnostic tests remain able to detect all known variants of COVID-19 including the new variant from South Africa, B.1.1.529
26. November 2021 07:37 ET
|
QuantuMDx Group Ltd
NEWCASTLE UPON TYNE, UK, 26 NOVEMBER 2021. QuantuMDx Group Limited (“QuantuMDx”), today confirms that both its SARS-CoV-2 assays for open PCR platforms and its rapid PCR device, Q-POC™, as well as its...
QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech
08. November 2021 07:00 ET
|
QuantuMDx Group Ltd
QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech Funds will be used to develop further multiplexing capabilities...
QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech
08. November 2021 02:00 ET
|
QuantuMDx Group Ltd
QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech Funds will be used to develop further multiplexing capabilities...